Carvolix Gains EUR 10m Tranche, Reaching EUR 20m in Financing

Carvolix, a French medical technology company, recently secured a new EUR 10 million tranche, pushing its total financing to EUR 20 million as part of an ongoing EUR 30 million program. This move underscores the confidence of strategic shareholders in Carvolix's innovations, particularly in AI-driven robotics. The funds are earmarked for Tavipilot's U.S. market entry and related regulatory efforts.

The company plans to utilize the financing to develop various products, focusing on Tavipilot's commercial deployment and obtaining FDA clearance. Carvolix aims to extend its financial runway beyond the end of September 2026 through potential venture debt agreements worth around EUR 25 million.

The transaction involves issuing 2,976,190 ordinary shares to existing shareholders at EUR 3.36 per share. These shares will be traded on Euronext Paris. Current investors include Edwards Lifesciences and Truffle Capital, each contributing EUR 5 million.